Long-term study of ML-007C-MA for schizophrenia
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This trial tests a new drug, ML-007C-MA, for adults with schizophrenia who may benefit from ongoing treatment. It aims to see how safe and effective the drug is over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of schizophrenia as confirmed by a doctor.
- You should be able to take medication regularly and live in a stable home environment.
- You need to have someone who can help with study assessments, like a family member or close contact.
- You cannot have other major mental health conditions that are causing your current problems.
- You should not be stopping a current effective antipsychotic just to join this study.
- You cannot have serious medical conditions, recent substance abuse, or high risk of self-harm.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called NBI-1117568 for adults with schizophrenia over a longer period of time. Participants will stop their current antipsychotics and take this new drug to see how well it works and how safe it is.
This trial tests an investigational medicine called NBI-1117568 in adults with schizophrenia who are currently having a relapse or worsening of symptoms and need to stay in the hospital. The goal is to see if the medicine is safe and effective.
This study tests an experimental drug (NBI-1117568) for people with schizophrenia who are currently in the hospital due to worsening symptoms. Participants stop their current antipsychotic and take the study drug to see if it can help control symptoms.
This trial tests an experimental medicine, LTX-001, for people with schizophrenia who are currently having a sudden worsening of symptoms. It aims to see if the drug can help reduce these acute symptoms.
This trial tests a new medication called SEP-363856 over a long period for people with schizophrenia who are currently stable. It looks at how well the drug works and its safety over time.
This trial tests a new medication called LB-102 for people with acute (sudden worsening of) schizophrenia. It aims to see if the drug helps reduce symptoms like hallucinations or disorganized thinking.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.